Home Newsfeeds GSK Says Regulatory Submission For Co’s Daprodustat Accepted Into Health Canada Review

News

GSK Says Regulatory Submission For Co’s Daprodustat Accepted Into Health Canada Review

-Reuters

byBenzinga Newsdesk

July 6, 2022

1 minute read

-Reuters

Attention Investors! Buy Mobileye At Current Levels, Analysts Say Post Q1 Results Snubbing Softness In Chinese EV Demand

By Anusuya Lahiri

April 28, 2:51 PM

Needham analyst Rajvindra Gill maintains Mobileye Global Inc (NASDAQ: MBLY) with a Buy and lowers the price target from

INTC

BTIG Maintains Buy on DexCom, Raises Price Target to $110

By Benzinga Newsdesk

October 10, 8:44 AM

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $92 to $110.

DXCM

Why Conn’s Shares Are Sliding Today

By Nabaparna Bhattacharya

June 1, 8:45 AM

Conn’s, Inc. (NASDAQ:CONN) reported a first-quarter FY24 sales decline of 16.3% year-over-year to $284.57 million, missing the consensus of $306.06 million. …

CONN

US Treasury Yield Curve Inverts Again As Dow Jones Index Plummets 130 Points

By Dylan Wechsler

July 5, 6:51 PM

The U.S. Treasury Yield Curve inverted Tuesday, July 5, while the SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA: DIA) fell 129.44 points. It's another sign that the economy is heading into a recession more and more each day.

DIA

GSK Says Regulatory Submission For Co’s Daprodustat Accepted Into Health Canada Review

Related Posts

Attention Investors! Buy Mobileye At Current Levels, Analysts Say Post Q1 Results Snubbing Softness In Chinese EV Demand

BTIG Maintains Buy on DexCom, Raises Price Target to $110

Why Conn’s Shares Are Sliding Today

US Treasury Yield Curve Inverts Again As Dow Jones Index Plummets 130 Points